Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis

American Journal of Nephrology

Volumn 18, Issue 3, 1998, Pages 186-192

  Opatrný Jr , Karel ^a   Opatrná, Sylvie ^a   Vit, Ladislav ^a   Opatrný, Karel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Chronic renal failure; Continuous ambulatory peritoneal dialysis; Fibrinolysis; Thrombosis

Indexed keywords

ANTIGEN; DIALYSIS FLUID; GLUCOSE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; ENZYME BLOOD LEVEL; FEMALE; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; MALE; PATIENT MONITORING; PERITONEAL CAVITY; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; THROMBOSIS; TIME;

ADULT; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 7144223420     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000013335     Document Type: Article

References (23)

1. Vigano G, Remuzzi G: Bleeding and coagulation abnormalities; in Massry SG, Glassock RJ (eds): Massry and Glassock's Textbook of Nephrology, ed. 3. Baltimore, Williams & Wilkins, 1995, pp 1373-1378.
2. Raine AEG, MacMahon SH, Selwood NH, Wing AJ, Brunner FP: Mortality from myocardial infarction in patients on renal replacement therapy in the UK. Nephrol Dial Transplant 1991;6:902.
3. Murphy BG, Hill CM, Middleton D, Doherty CC, Brown JH, Nelson WE, Kernohan RM, Keane PK, Douglas JF, McNamee PT: Increased renal allograft thrombosis in CAPD patients. Nephrol Dial Transplant 1994;9: 1166-1169.
4. Jones CL, Andrew M, Eddy A, O'Neil M, Ish Shalom N, Balfe JW: Coagulation abnormalities in chronic peritoneal dialysis. Pediatr Nephrol 1990;4.152-155.
5. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076-1079.
6. Collen D, Lijnen HR: The fibrinolytic enzyme system; in Sawaya R (ed): Fibrinolysis and the Central Nervous System. Philadelphia, Hanley &Belfus. 1990,pp 14-25.
7. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP: Peritoneal equilibration test. Pent Dial Bull 1987;7:138-147.
8. Canavese C, Stratta P, Pacitti A, Mangiarotti G, Racca M, Oneglio R, Vercellone A: Impaired fibrinolysis in uremia: Partial and variable correction by four different dialysis regimes. Clin Nephrol 1982;17:82-89.
9. Brommer EJP, Schicht I, Wijnagaards G, Verheijen JH, Rijken DC: Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients. Thromb Haemost 1984;52:311-314.
10. Opatmý K Jr, Vít L, Šefrna F, Válek A: Fibrinolysis in patients with chronic renal failure after 1-deamino-8-D-arginine vasopressin. J Nephrol 1991;4:233-238.
11. Opatrný K Jr, Vít L, Opatrná S, Bodláková B, Sulková S, Opatrný K: Hypofibrinolysis after stimulation by venous occlusion in hemodialysis patients and the effect of erythropoietin. Nieren Hochdruckkr 1995;24:324-328.
12. Nordt TK, Sawa H, Fujii S, Sobel BE: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995,91:764-770.
13. Opatrný K Jr, Spustová V: Glycemia-insulin relationship in hemodialysis. Bratisl Lék Listy 1993;94:209-212.
14. Opatrný K Jr, Opatrný K. Vít L, Racek J, Válek A: What are the factors contributing to the changes in tissue-type plasminogen activator during haemodialysis? Nephrol Dial Transplant 1991;6(suppl 3):26-30.
15. Kluft C, Jie AFH, Rijken DC, Verheijen JH: Daytime fluctuations in blood of tissue-type plaminogen activator (t-PA) and its fast-acting inhibitor (PAI-1). Thromb Haemost 1988;59: 329-332.
16. Sitter T, Spannagl M, Schiffl H, Held E, van Hinsbergh VWM, Kooistra T: Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: The role of mesothelial cells. Nephrol Dial Transplant 1995;10:677-683.
17. Gries E, Kopp J, Thomae U, Kuhlmann H: Relation of intraperitoneal and intravascular coagulation and fibrinolysis related antigens in peritoneal dialysis. Thromb Haemost 1990;63: 356-360.
18. Selgas R, Cuesta MV, Rinon C, Romero JR, de Alvaro F, Bajo MA, Sanchez-Sicilia L: Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD. Adv Pent Dial 1992;8:160-165.
19. Freyria AM, Paul J, Belleville J, Rissoan MC, Fuselier M, Eloy R: Evaluation of macrophage procoagulant and fibrinolytic activities induced by peritoneal dialysis solutions. J Lab Clin Med 1990;117:194-201.
20. Vaziri ND, Shah GM, Winer RL, Gonzales E, Patel B, Alikhani S, Nguyen QX, Yamamoto J: Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989;53:173-180.
21. Cavagna R, Schiavon R, Tessarin C, Papa N, Scorrano D, Casol D, De Sivestro L: Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis. Pent Dial Int 1993;13(suppl 2):402-405.
22. Bertoli M, Gasparotto ML, Vertolli U, Ruffatti A, Urso M, Romagnoli GF: Hypercoagulability in CAPD patients during peritonitis; in Smeby LC, Jørstad ST, Widerøe T-E (eds): Immune and Metabolic Aspects of Therapeutic Blood Purification Systems. Basel, Karger, 1986, pp 287-290.
23. Gagnon RF, Richards GK, Morcos R: Urokinase enhancement of rifampin activity against experimental S epidermidis biofilms in spent pd fluid. J Am Soc Nephrol 1995;6:530.